Summary#
This bill would make most lawsuits about preterm (specialized) infant formula regulated by the FDA eligible to be heard in federal court. It adds a new federal-jurisdiction rule for civil claims tied to preterm infant formula and lets any defendant remove such cases from state court to federal court without needing all defendants to agree. The stated goal is to protect the supply of specialized preterm infant formula and to promote uniform federal handling of related claims.
- Main change: Federal district courts would have original jurisdiction over civil actions alleging injury from preterm infant formula regulated by the FDA when there is diversity of citizenship (plaintiffs and defendants from different states) or a foreign defendant.
- Removal change: Any defendant may remove qualifying state-court cases to federal court without consent from the other defendants.
- Scope: The bill applies to cases pending when the law starts and to cases filed after enactment, regardless of the state court filing date.
- Policy goal stated in the bill: Prevent forum-shopping in state courts and provide uniform federal adjudication to protect availability of specialized preterm formula.
What it means for you#
- Parents of preterm babies / Plaintiffs: If you sue over injury you say was caused by specialized preterm infant formula, your case may end up in federal court rather than state court if the parties are from different states or a defendant is foreign.
- Manufacturers, distributors, hospitals, and other defendants: Companies and institutions sued over preterm formula can move state cases to federal court more easily. Any single defendant can remove the case without getting agreement from the other defendants.
- State courts: Fewer of these cases may remain in state court because federal courts will have jurisdiction and removal will be easier.
- Federal courts: Federal judges could see more cases about preterm infant formula. The bill preserves the ability of the Judicial Panel on Multidistrict Litigation to centralize related cases.
- Medical providers and hospitals that use or order preterm formula: The bill does not directly change medical rules or FDA oversight of formula, but litigation over formula is more likely to be handled in federal court.
What is unclear:
- The bill does not define precisely which products count as "preterm infant formula regulated by the Food and Drug Administration."
- The bill does not say whether the usual federal amount-in-controversy requirement still applies to these cases. It may be unclear how courts will interpret that.
Expenses#
No publicly available information.
- This change could increase federal court caseload and related administrative costs.
- Allowing easier removal may shift litigation costs from state courts to federal courts.
- Defendants may face higher litigation costs if more cases are litigated in federal court.
- There is no fiscal estimate or budget note attached to the bill text provided.
Proponents' View#
The bill appears intended to address these problems and benefits:
- The bill appears intended to keep the supply of specialized preterm infant formula stable by avoiding litigation outcomes that proponents fear could limit domestic supply.
- It could be seen as promoting uniform legal rules and remedies by having federal courts handle these cases nationwide.
- Supporters may argue that federal courts are better placed to resolve cases about products under federal oversight (FDA-regulated products).
- Making removal easier could reduce what the bill calls "forum shopping" (choosing favorable state courts), which supporters may see as fairer and more predictable.
Opponents' View#
Possible concerns or trade-offs based on the bill’s design:
- One concern is that plaintiffs lose choice of forum. Easier removal could force plaintiffs into federal court even when they preferred state court procedures or juries.
- The bill does not clearly define which formulas are covered, which could create disputes over whether a case qualifies for federal jurisdiction.
- It is unclear whether the usual amount-in-controversy threshold applies; that legal uncertainty could lead to early litigation over jurisdiction.
- Centralizing cases in federal court could disadvantage smaller plaintiffs who may find federal litigation more costly or complex.
- The change may increase workload for federal courts and shift costs from states to the federal system, but the bill provides no estimate of these costs.